Gabapentin
Product Images NDC 53002-4423

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 53002-4423). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

A text panel showing the formula to estimate creatinine clearance (CLCr). The formula calculates CLCr based on age, weight, serum creatinine, and includes a correction factor for female patients. This is typically used in dosing calculations or kidney function assessment.*

FDA Label Image

1 (Image 2)

Gabapentin 300 mg Capsules, a multi-colored capsule with a yellow body and a red cap imprinted with 'RPK 300'. Packaged by RPK Pharmaceuticals, Inc. Product NDC: 53002-4423.*

FDA Label Image

1 (Image 3)

Chemical structure of gabapentin, illustrating its molecular arrangement with carbon, hydrogen, nitrogen, and oxygen atoms. The schematic depicts gabapentin's characteristic ring and side chains used to identify its chemical composition.*

FDA Label Image

1 (Image 4)

The image shows a white capsule blister pack for Gabapentin by RPK Pharmaceuticals, Inc. Each capsule is white and oblong-shaped. No strength or quantity information is visible on the blister shown.*

FDA Label Image

1 (Image 5)

Chemical structure of Gabapentin showing a cyclohexane ring with two substituents: an aminomethyl group (CH2NH2) and an acetic acid group (CH2CO2H).*

FDA Label Image

1 (Image 6)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The Gabapentin group shows a notable decrease in pain scores over time compared to placebo.*

FDA Label Image

2 (Image 7)

A line graph showing mean pain score over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score, with decreases over time for gabapentin doses compared to placebo.*

FDA Label Image

3 (Image 8)

A bar chart comparing percentages of response rates in two studies, Study 1 and Study 2. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin (GBP) 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

4 (Image 9)

A scatter plot showing the percentage difference at various daily doses (600, 900, 1200, 1800 mg) of Gabapentin. The plot compares data from three studies labeled 'a', 'b', and 'c', represented by different colored and shaped markers.*

FDA Label Image

Label Image (Lbl530024423)

Label for Gabapentin 300 mg capsules by RPK Pharmaceuticals, Inc., containing 100 capsules. The label includes dosage instructions to take one capsule three times daily or as directed, and has spaces for patient and prescriber information. The product is marked Rx only and the label features various official codes and lot information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.